USPTO serial 98808648
ITAC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- KHOURI, SANI PHILIPPE
- Law office
- TMO LAW OFFICE 110
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with ITAC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Norman P. Soloway
Norman P. Soloway Hayes Soloway P.C.4640 E Skyline DriveTucson, AZ 85718United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cancer; Pharmaceuticals for the treatment of cancer; Chemicopharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for veterinary use for the treatment of cancer; Chemical preparations for pharmaceutical purposes for the treatment of cancer; Pharmaceutical preparations for human use for the treatment of cancer; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for use in oncology; Diagnostic preparations for medical purposes; Diagnostic agents for pharmaceutical use; Diagnostic agents for medical use; Diagnostic preparations for veterinary purposes; Clinical diagnostic reagents; Diagnostic chemical reagents for medical use; Anticancer drugs; Compounds for treating cancer; Anti-cancer preparations; Anti-cancer preparations of chemical origin; Biopharmaceuticals for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Chemotherapeutics; Antibodies for medical purposes; Antibody-drug conjugates for the treatment of cancer; Pharmaceutical preparations for immunotherapy | ACTIVE | — |
| 042 | Pharmaceutical research services; Medical and pharmacological research services; Pharmaceutical product development; Development of pharmaceutical preparations and medicines; Consultancy relating to pharmaceutical research and development; Provision of research services in the field of toxicology, stem cell and medical research; Scientific research; Medical research; Biomedical research services; Research relating to biotechnology; Research on the subject of pharmaceuticals; Consultancy relating to research in the field of pharmacogenetics; Research and development in the pharmaceutical and biotechnology fields; Research and development in the field of diagnostic preparations; Research and development in the field of biotechnology; Research and development for the pharmaceutical industry; Research and development services in the field of antibody technology; Research and development services in the field of antibodies and antibody-drug conjugates; Laboratory services relating to the production of monoclonal antibodies and antibody-drug conjugates | ACTIVE | — |
| 044 | Pharmaceutical services, namely, pharmaceutical compounding services in the field of oncology; Pharmaceutical advice; Pharmaceutical services, namely, pharmaceutical compounding services; Consultancy and information services relating to pharmaceutical products; Providing healthcare information regarding cancer drugs and cancer treatment | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 27, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 27, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 29, 2026 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Apr 29, 2026 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Apr 29, 2026 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Apr 15, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 17, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 17, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 17, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 3, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 3, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 3, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 24, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 24, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 22, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 21, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 18, 2024 | NWAP | NEW APPLICATION ENTERED | — |